Mark Elliott Boulding net worth and biography

Mark Boulding Biography and Net Worth

Mr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. He also serves as a director of one and as co-secretary of two subsidiaries of PTC. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two Washington, D.C.-based law firms. Mr. Boulding received a J.D. from the University of Michigan and a B.A. from Yale College.

What is Mark Elliott Boulding's net worth?

The estimated net worth of Mark Elliott Boulding is at least $3.10 million as of September 20th, 2022. Mr. Boulding owns 61,110 shares of PTC Therapeutics stock worth more than $3,102,555 as of September 28th. This net worth evaluation does not reflect any other investments that Mr. Boulding may own. Additionally, Mr. Boulding receives a salary of $824,090.00 as VP at PTC Therapeutics. Learn More about Mark Elliott Boulding's net worth.

How old is Mark Elliott Boulding?

Mr. Boulding is currently 61 years old. There are 6 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 76 years old. Learn More on Mark Elliott Boulding's age.

What is Mark Elliott Boulding's salary?

As the VP of PTC Therapeutics, Inc., Mr. Boulding earned a total compensation package of $4,292,842.00 in 2021. Mr. Boulding earned a salary of $503,938.00, stock awards of $678,198.00, options awards of $2,790,550.00, non-equity compensation of $298,700.00, and other compensation of $21,456.00.The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, CEO & Exec. Director, who commands a salary of $1,640,000.00 per year. Learn More on Mark Elliott Boulding's salary.

How do I contact Mark Elliott Boulding?

The corporate mailing address for Mr. Boulding and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected] Learn More on Mark Elliott Boulding's contact information.

Has Mark Elliott Boulding been buying or selling shares of PTC Therapeutics?

Within the last three months, Mark Elliott Boulding has sold $64,680.00 in shares of PTC Therapeutics stock. Most recently, Mark Elliott Boulding sold 1,176 shares of the business's stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $55.00, for a transaction totalling $64,680.00. Following the completion of the sale, the vice president now directly owns 61,110 shares of the company's stock, valued at $3,361,050. Learn More on Mark Elliott Boulding's trading history.

Who are PTC Therapeutics' active insiders?

PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Dawn Svoronos (Director), and Christine Utter (CAO). Learn More on PTC Therapeutics' active insiders.

Are insiders buying or selling shares of PTC Therapeutics?

During the last twelve months, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 53,910 shares worth more than $2,324,969.42. The most recent insider tranaction occured on September, 20th when VP Mark Elliott Boulding sold 1,176 shares worth more than $64,680.00. Insiders at PTC Therapeutics own 6.0 % of the company. Learn More about insider trades at PTC Therapeutics.

Information on this page was last updated on 9/20/2022.

Mark Elliott Boulding Insider Trading History at PTC Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2022Sell1,176$55.00$64,680.0061,110View SEC Filing Icon  
4/13/2022Sell2,276$45.17$102,806.9261,110View SEC Filing Icon  
4/5/2022Sell5$45.00$225.0061,110View SEC Filing Icon  
2/10/2022Sell17,935$45.03$807,613.05View SEC Filing Icon  
2/1/2022Sell779$40.00$31,160.00View SEC Filing Icon  
1/7/2022Sell885$38.52$34,090.20View SEC Filing Icon  
7/8/2021Sell7,805$45.22$352,942.10View SEC Filing Icon  
2/1/2021Sell778$56.96$44,314.8848,374View SEC Filing Icon  
1/5/2021Sell772$62.37$48,149.6438,952View SEC Filing Icon  
7/7/2020Sell30,625$55.12$1,688,050.0052,849View SEC Filing Icon  
7/5/2019Sell15,312$44.74$685,058.8832,805View SEC Filing Icon  
7/1/2019Sell181,667$45.00$8,175,015.00View SEC Filing Icon  
6/28/2019Sell77,575$45.00$3,490,875.00View SEC Filing Icon  
6/8/2015Sell56,849$55.04$3,128,968.96View SEC Filing Icon  
3/20/2015Sell21,142$68.12$1,440,193.04View SEC Filing Icon  
3/20/2014Sell10,049$30.96$311,117.0432,235View SEC Filing Icon  
See Full Table

Mark Elliott Boulding Buying and Selling Activity at PTC Therapeutics

This chart shows Mark Elliott Boulding's buying and selling at PTC Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PTC Therapeutics Company Overview

PTC Therapeutics logo
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Read More

Today's Range

Now: $51.23
Low: $50.12
High: $51.52

50 Day Range

MA: $50.13
Low: $43.25
High: $53.85

2 Week Range

Now: $51.23
Low: $25.01
High: $55.58


25,945 shs

Average Volume

615,834 shs

Market Capitalization

$3.66 billion

P/E Ratio


Dividend Yield